Clinical Trial Update: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating oral decitabine with tetrahydrouridine as epigenetic priming to enhance pembrolizumab in inoperable/unresectable locally advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Esophagus
• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tetrahydrouridine (tetrahydrouridine)
• oral decitabine (decitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-05-31